Pembrolizumab provided long-term overall survival benefit in second-line treatment and can be effectively used for retreatment after disease progression.
The team wants to create NK cell therapies from induced pluripotent stem cells and aims to achieve proof-of-concept for their technology in multiple myeloma.
The aim of the study is to establish a tumor registry based on blood and bone marrow samples from cancer patients with linked outcomes data, which the firm can use for precision drug development.
Increasing understanding of complex tumor biology is reshaping clinical trials in the age of precision medicine, though some view these changes with concern.
The CVS-Tempus partnership aims to streamline the cancer care process for patients from the point of prescribing onwards and connect patients with local trials.
Researchers at BostonGene and Weill Cornell Medicine hope their approach may provide a more complete and precise characterization of diffuse large B-cell lymphomas.
